Premium
Validation of effect of Pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice
Author(s) -
Medhi Bikash,
Aggrawal Raman,
Chakrabarty Amitava
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.716.13
Subject(s) - neuroprotection , pioglitazone , medicine , ischemia , cerebral edema , agonist , oxidative stress , pharmacology , edema , brain edema , malondialdehyde , anesthesia , endocrinology , diabetes mellitus , receptor , type 2 diabetes
Objective: Present study was carried out to investigate the possible neuroprotective effect of pioglitazone on acute phase changes in mice model of cerebral ischemia. Materials and Methods: Male mice weighing 20–30 gm were used in the study. BCCAO model was used to induce partial global cerebral ischemia. Animals were divided into 3 groups and following parameters were assessed (infarct size, brain edema, MDA, SOD, Catalase, GPx &TNF (). Postischemic seizure susceptibility was assessed using subconvulsive dose of PTZ (30 mg/kg i.p.). Results: BCCAO induced significant brain infarct size and edema in control group with increase oxidative stress. Pioglitazone (20 mg/kg orally) has shown neuroprotective effects by reducing cerebral infarct size significantly as compared to control group. Postischemic seizure susceptibility was also reduced as number of positive responders decreased to a significant number. Brain edema was subsided to a significant level. Pioglitazone has reduced the plasma TNF‐ a and improved antioxidant parameters levels as compared to ischemia group significantly. Conclusion: Pioglitazone showed neuroprotection against ischemic insult suggesting the role of PPAR ? agonist as neuroprotective agents. (Supported by PGIMER, Chandigarh, India.) Key words: Cerebral ischemia, pioglitazone, PPAR‐gamma, neuroprotection